Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Abvc Biopharma (ABVC) over the last 8 years, with Q3 2025 value amounting to $25963.0.

  • Abvc Biopharma's Gains from Investment Securities fell 8996.44% to $25963.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$764997.0, marking a year-over-year decrease of 39569.67%. This contributed to the annual value of -$532769.0 for FY2024, which is 5718.13% up from last year.
  • As of Q3 2025, Abvc Biopharma's Gains from Investment Securities stood at $25963.0, which was down 8996.44% from $107239.0 recorded in Q2 2025.
  • Over the past 5 years, Abvc Biopharma's Gains from Investment Securities peaked at $2.6 million during Q1 2024, and registered a low of -$1.3 million during Q3 2023.
  • In the last 5 years, Abvc Biopharma's Gains from Investment Securities had a median value of $107239.0 in 2025 and averaged $156795.2.
  • In the last 5 years, Abvc Biopharma's Gains from Investment Securities plummeted by 1097626.35% in 2023 and then soared by 16999230.77% in 2024.
  • Over the past 5 years, Abvc Biopharma's Gains from Investment Securities (Quarter) stood at $1.3 million in 2021, then plummeted by 100.14% to -$1786.0 in 2022, then skyrocketed by 10072.96% to $178117.0 in 2023, then tumbled by 722.2% to -$1.1 million in 2024, then soared by 102.34% to $25963.0 in 2025.
  • Its last three reported values are $25963.0 in Q3 2025, $107239.0 for Q2 2025, and $210040.0 during Q1 2025.